Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about a user who started using finasteride to address crown balding, noticing reduced hair shedding and halted progression of male pattern baldness. The user also used a dermal stamp and expressed optimism about potential regrowth, despite a slight decrease in libido.

The conversation discusses the potential of Replicel/Shiseido treatment for hair loss, questioning its effectiveness, whether it grows new follicles, and its market release timeline. It also compares Replicel to other competitors like Kyocera/RIKEN/Tsuji.

User reported hair regrowth and thicker hair after using rosemary oil, zinc, biotin, vitamin D, and a better diet. They believe rosemary oil contributed the most to the improvement.

Breezula's development has stalled, leaving users disappointed. The conversation includes skepticism about its approval and effectiveness.

The user is pleased with their hair growth results after using oral minoxidil (2.5mg) for 3 months and finasteride (1mg) for 4 months, despite experiencing significant shedding initially. They prefer oral treatments over topical due to convenience and concerns about toxicity to pets.

A trial of verteporfin for hair regeneration, with pictures comparing the original and current status, as well as links to other resources discussing the efficacy of this treatment in combination with Minoxidil, Finasteride, and RU58841.

A 23-year-old male has been using oral dutasteride and minoxidil for 1.5 years for temple recession, adding topical minoxidil and tretinoin 5-6 months ago, and recently adjusted thyroid medication and added iron supplements due to deficiencies. He noticed some baby hairs but no significant growth yet, and reports no shedding on dutasteride.

HMI-115 is a new drug developed by Bioinvent and licensed by Bayer, with mixed opinions on its potential effectiveness. Some users are skeptical and prefer proven treatments like Minoxidil, finasteride, and RU58841.

The post and conversation are about the user's experience with oral minoxidil for hair loss. Some users noticed increased hair density, while others experienced unwanted hair growth in different areas of the body.

Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.

User has been using 1.25 mg finasteride and 2.5 mg minoxidil daily for 5 months, along with 5000 mcg biotin for 1.5 months. They noticed peach fuzz growth around month 4 and are seeking confirmation if this indicates hair regrowth.

Tazarotene may be more effective than tretinoin when combined with topical minoxidil for hair loss due to its selective binding to RAR-beta and gamma, though it can cause irritation. Tazarotene's potency can lead to indirect inflammatory reactions despite potentially causing less irritation than tretinoin.

The user is using minoxidil, finasteride, dermarolling, and other treatments for hair regrowth, showing promising results in the temple area. Despite some skepticism, there is optimism about potential improvement.

The user, Salty-Peace-577, shared their 5-month update on using 0.5mg oral finasteride and 2.5mg oral minoxidil for hair loss. They experienced significant hair growth, particularly in their eyebrows, and shared their regimen and tips for hair growth. Some users in the conversation also discussed the side effects they experienced with different dosages of the medications.

The user is seeking an alternative to Rogaine (Minoxidil) due to facial puffiness. Another user responded that Redensyl was ineffective for them.

The user is experiencing positive hair regrowth after two months of using oral finasteride (0.5 mg) and minoxidil (2.5 mg) and is considering a hair transplant. They are seeking advice on surgeons closer to the U.S. and discussing potential side effects and alternative treatments.

A 25-year-old shared progress on hair regrowth after 2.5 years of oral finasteride and over a year of inconsistent topical minoxidil use, noting significant density gains despite a long-standing receded hairline. The user emphasized patience, as noticeable improvements took about 18 months, and mentioned using Ascend brand finasteride and occasional Nizoral shampoo for seborrheic dermatitis.

Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.

Dutasteride treatment may decrease sperm concentration, but levels remain above WHO recommendations and recover after discontinuation. The study has limitations, including small sample size and lack of pre-treatment sperm data, and does not assess other fertility factors.

The user applies a topical solution containing minoxidil, finasteride, dutasteride, retinoic acid, and hydrocortisone to address scalp inflammation and is considering adding cetirizine to the mix. They are calculating the correct amount of cetirizine to add to their formula and have paused this approach to retry oral minoxidil.

The user experienced improved hair density after 3 months of oral finasteride and 1 month of oral minoxidil, along with changes in diet, supplements, and hair care. They are unsure if the improvement is due to these treatments or changes in hair care habits.

P-1075 is a more potent hair growth agent than Minoxidil, but it poses significant heart risks, making it unsafe for use. Despite promising results in macaques, concerns about its cardiotoxicity in rats have halted its development.

The user experienced negative side effects from oral minoxidil, including cardiac issues and excessive sweating, and decided to switch to topical minoxidil while using other treatments like RU58841, Setipiprant, Azelaic acid, and latanoprost. Another user suggested splitting the oral minoxidil dose to reduce side effects.

The conversation discusses a new hair growth treatment that showed a 14 hairs/cm2 increase in a trial, with mixed opinions on its effectiveness and potential cost. Some users are hopeful about combining it with existing treatments like oral minoxidil for better results.

The effects of smoking cigarettes on DHT levels and its potential effect on hair loss, with some people sharing experiences in relation to their own hair loss. Various treatments for reducing or reversing hair loss were discussed, such as quitting smoking, minoxidil, finasteride and RU58841.

Pirfenidone is suggested to treat fibrosis and baldness by blocking inflammation markers and reducing collagen. It is also available as a gel for scar removal.

A 31-year-old man shared his hair growth progress from July 2024 to March 2026 using oral finasteride (1mg) and minoxidil (2.5mg), with no significant side effects. He is considering switching treatments but is advised to continue with the current regimen due to its effectiveness.

A 44-year-old man has been using finasteride 1mg daily and minoxidil 5% foam for 19 months to address hair loss, with mixed results and continued shedding. Suggestions include trying oral minoxidil, microneedling, and possibly a hair transplant for better cosmetic density.

A 27-year-old male experienced significant hair regrowth in two months using a daily oral 3-in-1 pill containing 1.1mg finasteride, 5mg minoxidil, and 1mg biotin from LockLab, with no side effects reported. The user also uses a derma-stamp twice a week to promote blood flow and stimulate growth.

The conversation is about a user's hair regrowth progress using topical minoxidil, with plans to start finasteride. The user also takes Vitamin D and washes their hair 2-3 times a week.